Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Evercore ISI Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN)

Tipranks - Tipranks - Fri Dec 19, 2025

Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Viridian Therapeutics yesterday and set a price target of $42.00.

Claim 50% Off TipRanks Premium and Invest with Confidence

Clark-Gartner covers the Healthcare sector, focusing on stocks such as AbbVie, Vera Therapeutics, and Insmed. According to TipRanks, Clark-Gartner has an average return of 25.6% and a 66.67% success rate on recommended stocks.

In addition to Evercore ISI, Viridian Therapeutics also received a Buy from Truist Financial’s Gregory Renza in a report issued on December 16. However, on December 9, TR | OpenAI – 4o reiterated a Hold rating on Viridian Therapeutics (NASDAQ: VRDN).

See today’s best-performing stocks on TipRanks >>

Based on Viridian Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $70.57 million and a GAAP net loss of $34.6 million. In comparison, last year the company earned a revenue of $86 thousand and had a GAAP net loss of $76.69 million

Read More on VRDN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).